Diabetic cardiomyopathy: how much does it depend on AGE?
Open Access
- 1 June 2008
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 154 (4), 725-726
- https://doi.org/10.1038/bjp.2008.121
Abstract
Diabetic cardiomyopathy refers to dysfunction of cardiac muscle in patients with diabetes that cannot be directly ascribed to hypertension, coronary heart disease or other defined cardiac abnormalities per se. The development of diabetic cardiomyopathy may involve several distinct mechanisms, including increased formation of advanced glycation end products (AGEs) secondary to hyperglycaemia. AGEs may alter structural proteins and lead to increased arterial and myocardial stiffness. Therefore, therapies that prevent or retard development of AGEs in diabetes may be valuable strategies to treat or prevent diabetic cardiomyopathy. In this issue of British Journal of Pharmacology, Wu and colleagues demonstrate that aminoguanidine (inhibitor of AGE formation and protein cross‐linking) treatment of a rat model of type I diabetes (rats made insulin deficient with streptozotocin and nicotinamide treatment) ameliorates detrimental changes in left ventricular structure and function. Results from this study are in agreement with previous investigations, suggesting that aminoguanidine is effective in preventing cardiac hypertrophy and arterial stiffening in experimental animal models of diabetes and emphasize the potential pathogenic role of AGEs in diabetic cardiomyopathy. British Journal of Pharmacology (2008) 154, 725–726; doi:10.1038/bjp.2008.121; published online 14 April 2008Keywords
This publication has 10 references indexed in Scilit:
- Effect of a Multifactorial Intervention on Mortality in Type 2 DiabetesNew England Journal of Medicine, 2008
- Aminoguanidine prevents arterial stiffening in a new rat model of type 2 diabetesEuropean Journal of Clinical Investigation, 2006
- Diabetic Cardiomyopathy: Evidence, Mechanisms, and Therapeutic ImplicationsEndocrine Reviews, 2004
- Randomized Trial of an Inhibitor of Formation of Advanced Glycation End Products in Diabetic NephropathyAmerican Journal of Nephrology, 2004
- Novel inhibitors of advanced glycation endproductsArchives of Biochemistry and Biophysics, 2003
- Design and Baseline Characteristics for the Aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II)Controlled Clinical Trials, 1999
- Effects of glucose intolerance on myocardial function and collagen-linked glycation.Diabetes, 1999
- Advanced Glycosylation End Products in Tissue and the Biochemical Basis of Diabetic ComplicationsNew England Journal of Medicine, 1988
- Aminoguanidine Prevents Diabetes-Induced Arterial Wall Protein Cross-LinkingScience, 1986
- New type of cardiomyopathy associated with diabetic glomerulosclerosisThe American Journal of Cardiology, 1972